MX382949B - Formulaciones tópicas de detomidina. - Google Patents
Formulaciones tópicas de detomidina.Info
- Publication number
- MX382949B MX382949B MX2019008115A MX2019008115A MX382949B MX 382949 B MX382949 B MX 382949B MX 2019008115 A MX2019008115 A MX 2019008115A MX 2019008115 A MX2019008115 A MX 2019008115A MX 382949 B MX382949 B MX 382949B
- Authority
- MX
- Mexico
- Prior art keywords
- topical
- detomidine
- subject
- formulations
- formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- JXMXDKHEZLKQPB-UHFFFAOYSA-N detomidine Chemical compound CC1=CC=CC(CC=2[N]C=NC=2)=C1C JXMXDKHEZLKQPB-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001894 detomidine Drugs 0.000 title abstract 2
- 230000000699 topical effect Effects 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 abstract 2
- 230000009885 systemic effect Effects 0.000 abstract 2
- 239000012049 topical pharmaceutical composition Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443174P | 2017-01-06 | 2017-01-06 | |
| PCT/US2018/012579 WO2018129313A1 (en) | 2017-01-06 | 2018-01-05 | Topical detomidine formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019008115A MX2019008115A (es) | 2019-10-24 |
| MX382949B true MX382949B (es) | 2025-03-13 |
Family
ID=61054537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008115A MX382949B (es) | 2017-01-06 | 2018-01-05 | Formulaciones tópicas de detomidina. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190343805A1 (enExample) |
| EP (1) | EP3565526B1 (enExample) |
| JP (1) | JP2020505322A (enExample) |
| KR (1) | KR20190110561A (enExample) |
| CN (1) | CN110114059A (enExample) |
| AU (1) | AU2018205217B2 (enExample) |
| BR (1) | BR112019011961A2 (enExample) |
| CA (1) | CA3049389A1 (enExample) |
| DK (1) | DK3565526T3 (enExample) |
| ES (1) | ES2982022T3 (enExample) |
| HU (1) | HUE068070T2 (enExample) |
| IL (1) | IL266448B2 (enExample) |
| MX (1) | MX382949B (enExample) |
| PL (1) | PL3565526T3 (enExample) |
| WO (1) | WO2018129313A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210137830A1 (en) * | 2018-07-11 | 2021-05-13 | Clexio Biosciences Ltd. | Topical detomidine formulations |
| WO2020016827A1 (en) * | 2018-07-18 | 2020-01-23 | Clexio Biosciences Ltd. | Purified crystalline detomidine hydrochloride monohydrate, anhydrate and free base with low amounts of iso-detomidine and other impurities by recrystallisation in water |
| KR20220002950A (ko) * | 2019-05-01 | 2022-01-07 | 클렉시오 바이오사이언시스 리미티드 | 소양증의 치료 방법 |
| WO2020222192A1 (en) | 2019-05-01 | 2020-11-05 | Clexio Biosciences Ltd. | Methods of treating pruritus |
| FR3169318A1 (fr) | 2024-12-11 | 2026-06-12 | Tarian Pharma | Composition comprenant un vasoconstricteur pour prevenir et/ou traiter des neuropathies peripheriques et/ou douleurs neuropathiques |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10256774A1 (de) * | 2002-12-05 | 2004-06-24 | Lts Lohmann Therapie-Systeme Ag | Transmucosale und transdermale Arzneimittel mit verbesserter Wirkstoffresorption |
| FI20041425A0 (fi) * | 2004-11-05 | 2004-11-05 | Orion Corp | Transmukosaalinen veterinäärinen koostumus |
| EP2558101A4 (en) * | 2010-04-15 | 2013-09-18 | Univ Mcgill | TOPICAL TREATMENTS OF PAIN |
| WO2013076160A1 (en) * | 2011-11-21 | 2013-05-30 | Université Libre de Bruxelles | Sustained release formulations useful in the treatment of diseases |
| EP2803668A1 (en) * | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| JP6621747B2 (ja) * | 2013-08-14 | 2019-12-18 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 疼痛を制御するための組成物及び方法 |
| US20150057351A1 (en) * | 2013-08-22 | 2015-02-26 | Sucampo Ag | Method for treating neuropathic pain |
-
2018
- 2018-01-05 ES ES18701853T patent/ES2982022T3/es active Active
- 2018-01-05 JP JP2019531615A patent/JP2020505322A/ja active Pending
- 2018-01-05 BR BR112019011961-2A patent/BR112019011961A2/pt not_active IP Right Cessation
- 2018-01-05 CN CN201880005492.XA patent/CN110114059A/zh active Pending
- 2018-01-05 CA CA3049389A patent/CA3049389A1/en active Pending
- 2018-01-05 PL PL18701853.6T patent/PL3565526T3/pl unknown
- 2018-01-05 EP EP18701853.6A patent/EP3565526B1/en active Active
- 2018-01-05 US US16/475,452 patent/US20190343805A1/en not_active Abandoned
- 2018-01-05 WO PCT/US2018/012579 patent/WO2018129313A1/en not_active Ceased
- 2018-01-05 IL IL266448A patent/IL266448B2/en unknown
- 2018-01-05 DK DK18701853.6T patent/DK3565526T3/da active
- 2018-01-05 AU AU2018205217A patent/AU2018205217B2/en not_active Ceased
- 2018-01-05 HU HUE18701853A patent/HUE068070T2/hu unknown
- 2018-01-05 KR KR1020197023046A patent/KR20190110561A/ko not_active Ceased
- 2018-01-05 MX MX2019008115A patent/MX382949B/es unknown
-
2023
- 2023-01-30 US US18/161,215 patent/US20230172909A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020505322A (ja) | 2020-02-20 |
| IL266448B2 (en) | 2023-11-01 |
| EP3565526B1 (en) | 2024-04-17 |
| ES2982022T3 (es) | 2024-10-14 |
| CA3049389A1 (en) | 2018-07-12 |
| HUE068070T2 (hu) | 2024-12-28 |
| US20230172909A1 (en) | 2023-06-08 |
| WO2018129313A1 (en) | 2018-07-12 |
| EP3565526A1 (en) | 2019-11-13 |
| PL3565526T3 (pl) | 2024-09-09 |
| BR112019011961A2 (pt) | 2019-11-05 |
| KR20190110561A (ko) | 2019-09-30 |
| IL266448B1 (en) | 2023-07-01 |
| AU2018205217B2 (en) | 2023-11-09 |
| IL266448A (en) | 2019-06-30 |
| MX2019008115A (es) | 2019-10-24 |
| CN110114059A (zh) | 2019-08-09 |
| AU2018205217A1 (en) | 2019-05-23 |
| US20190343805A1 (en) | 2019-11-14 |
| DK3565526T3 (en) | 2024-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017502092A1 (en) | Topical pharmaceutical compositions | |
| MX2016009666A (es) | Suministro topico de composiciones para la piel que tienen ph bajo. | |
| MX2010002392A (es) | Composiciones de brimonidina mejoradas para tratar eritema. | |
| MX2024000828A (es) | Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis. | |
| PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| PH12019502874A1 (en) | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments | |
| EP4552650A3 (en) | Methods and compositions for treatment of skin | |
| WO2020012415A3 (en) | Topical detomidine formulations | |
| RU2014150505A (ru) | Способ идентификации лигандов рецептора ahr, которые обладают терапевтической себосупрессивной активностью, и указанные лиганды | |
| FI4218725T3 (fi) | Pehmeiden antikolinergisten analogien formulaatio | |
| MX418886B (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo | |
| MX2022001736A (es) | Formulaciones y tratamientos topicos. | |
| PH12020552142A1 (en) | Composition for muscle relaxation | |
| MX2019008115A (es) | Formulaciones topicas de detomidina. | |
| SG10201908690WA (en) | Novel method of use and compositions | |
| MX2020007062A (es) | Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas. | |
| CA3198952A1 (en) | Gel, ointment, and foam formulations of tapinarof and methods of use | |
| MX379253B (es) | Formulaciones de oximetazolina estabilizadas y sus usos. | |
| MX2016008546A (es) | Reduccion de queloides utilizando alantoina topica. | |
| WO2014091146A3 (fr) | Utilisation cosmetique d'un extrait de germe de caroube en tant qu'agent actif amincissant | |
| WO2020170033A8 (en) | Method for treatment of moderate to severe erythema symptoms in rosacea patients | |
| SG11201909144VA (en) | Bacterial secretome for use in the treatment of skin lesions | |
| WO2020022976A3 (en) | A formulation comprising dexketoprofen | |
| MX2018013477A (es) | Acidos carboxilicos para tratar/prevenir una enfermedad de la piel. |